Abstract: Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.
Type:
Grant
Filed:
May 2, 2022
Date of Patent:
May 21, 2024
Assignee:
University of Kentucky Research Foundation
Inventors:
Lisa Cassis, Sean Thatcher, Yasir Alsiraj, Mark Ensor, Eric Blalock
Abstract: The present invention relates to a composition of branched fatty acids or esters thereof, the process for preparing such a composition and its use in various industrial fields, such as in lubricant, in cosmetics and in home care. More particularly, the present invention relates to a composition comprising at least 30% by weight of polybranched C10-C24 fatty acids or esters thereof, and a cyclic compound content ranging from 1% to 8% by weight, the weight percentage being given on the total weight of the composition.
Type:
Grant
Filed:
May 3, 2019
Date of Patent:
May 21, 2024
Assignee:
OLEON NV
Inventors:
Pieter Struelens, Andreas Lambin, Dirk Packet
Abstract: A method for controlling proteoglycan accumulation disease includes the use of a pharmaceutically efficient amount of a COX2 inhibitor NSAID.
Abstract: The present disclosure provides compositions comprising one or more compounds of general formula (I): wherein: R1 is H, —OMe, Me, or one or more electron withdrawing groups; R2 and R3 are each independently H or alkyl or, taken together, form a 4- to 8-membered heterocyclic ring with the adjacent nitrogen atom; R4 is H or alkyl; R5 is H or one or more electron donating groups; and n is 1 to 4.
Type:
Grant
Filed:
July 26, 2023
Date of Patent:
May 14, 2024
Assignee:
PTC Innovations, LLC
Inventors:
Pendleton Wickersham, Stephen Bendel, Todd Mathis, Christian Warren
Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.
Type:
Grant
Filed:
August 7, 2023
Date of Patent:
May 7, 2024
Assignee:
BOW RIVER LLC
Inventors:
Sundar Srinivasan, Christina Chow Wallen
Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
Type:
Grant
Filed:
September 22, 2022
Date of Patent:
May 7, 2024
Assignee:
Duke University
Inventors:
Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
Abstract: Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.
Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.
Type:
Grant
Filed:
November 7, 2019
Date of Patent:
April 30, 2024
Assignee:
THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Mi-La Cho, Dong-Yun Shin, Jong-Young Choi, Chul-Woo Yang, Sung-Hwan Park, Seon-Yeong Lee, Min-Jung Park, Joo-Yeon Jhun, Se-Young Kim, Hyeon-Beom Seo, Jae-Yoon Ryu, Keun-Hyung Cho
Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).
Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
Type:
Grant
Filed:
July 12, 2022
Date of Patent:
April 16, 2024
Assignee:
OrphAl Therapeutics Inc.
Inventors:
Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
Abstract: An energy-promoting composition includes an exogenous ketone body component that provides a source of caloric energy, a vasodilator component, a stimulant component, such as caffeine, and optionally a nootropic component. In most if not all cases, the vasodilator, stimulant, and nootropic components do not themselves provide a source of caloric energy but may increase metabolism of available caloric energy. The separate components beneficially and synergistically interact with one another to enhance the overall energy-promoting effect of the composition more rapidly and to a greater degree than if one or more of the components are omitted. The energy-promoting composition is also formulated to minimize the crash effect common to stimulants such as energy drinks.
Abstract: Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer metastasis, a health functional food, and a method for preventing or treating cancer metastasis using the same, containing a novel compound for inhibiting migration and invasion of cancer cells or a pharmaceutically acceptable salt thereof as an active ingredient.
Type:
Grant
Filed:
May 2, 2019
Date of Patent:
April 2, 2024
Assignee:
VSPHARMTECH
Inventors:
Byoung-Mog Kwon, Dong Cho Han, Yae Jin Yoon, Yu Jin Lee, Jiyoun Choi, Sangku Lee
Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Type:
Grant
Filed:
June 23, 2021
Date of Patent:
March 26, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Rao V. Kalla, Dmitry Koltun, Richard L. Mackman, Thao D. Perry, Dustin S. Siegel, Scott P. Simonovich